GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » Cyclically Adjusted PS Ratio

Theratechnologies (Theratechnologies) Cyclically Adjusted PS Ratio : 0.46 (As of Jun. 10, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Theratechnologies's current share price is $1.22. Theratechnologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was $2.65. Theratechnologies's Cyclically Adjusted PS Ratio for today is 0.46.

The historical rank and industry rank for Theratechnologies's Cyclically Adjusted PS Ratio or its related term are showing as below:

THTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.35   Med: 6.62   Max: 40.47
Current: 0.47

During the past years, Theratechnologies's highest Cyclically Adjusted PS Ratio was 40.47. The lowest was 0.35. And the median was 6.62.

THTX's Cyclically Adjusted PS Ratio is ranked better than
91.67% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs THTX: 0.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Theratechnologies's adjusted revenue per share data for the three months ended in Feb. 2024 was $0.329. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.65 for the trailing ten years ended in Feb. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Theratechnologies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Theratechnologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Cyclically Adjusted PS Ratio Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.06 5.30 6.35 3.70 0.59

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.41 0.35 0.59 0.55

Competitive Comparison of Theratechnologies's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Theratechnologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Cyclically Adjusted PS Ratio falls into.



Theratechnologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Theratechnologies's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.22/2.65
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theratechnologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, Theratechnologies's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0.329/125.4675*125.4675
=0.329

Current CPI (Feb. 2024) = 125.4675.

Theratechnologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 0.145 99.394 0.183
201408 0.000 99.315 0.000
201411 0.140 99.078 0.177
201502 0.239 99.078 0.303
201505 0.384 100.263 0.481
201508 0.446 100.579 0.556
201511 0.385 100.421 0.481
201602 0.393 100.421 0.491
201605 0.421 101.765 0.519
201608 0.414 101.686 0.511
201611 0.417 101.607 0.515
201702 0.385 102.476 0.471
201705 0.406 103.108 0.494
201708 0.477 103.108 0.580
201711 0.498 103.740 0.602
201802 0.433 104.688 0.519
201805 0.509 105.399 0.606
201808 0.690 106.031 0.816
201811 0.729 105.478 0.867
201902 0.785 106.268 0.927
201905 0.812 107.927 0.944
201908 0.837 108.085 0.972
201911 0.852 107.769 0.992
202002 0.817 108.559 0.944
202005 0.892 107.532 1.041
202008 0.730 108.243 0.846
202011 0.993 108.796 1.145
202102 0.729 109.745 0.833
202105 0.753 111.404 0.848
202108 0.752 112.668 0.837
202111 0.789 113.932 0.869
202202 0.780 115.986 0.844
202205 0.810 120.016 0.847
202208 0.875 120.569 0.911
202211 0.896 121.675 0.924
202302 0.823 122.070 0.846
202305 0.725 124.045 0.733
202308 0.862 125.389 0.863
202311 0.717 125.468 0.717
202402 0.329 125.468 0.329

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theratechnologies  (NAS:THTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Theratechnologies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.